arrow
S

Simone Thomas

University Hospital Regensburg
H指数:27
被引数:3,767

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms

MDG1011的首次人体研究,MDG1011是一种针对HLA-A*02:01限制性PRAME抗原的TCR-T疗法,用于高风险髓系和淋巴系肿瘤。

2025-09-250
OAAI
Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants
BRAIN
IF11.7
2024-07-181
PRE
TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations

TRPV4神经肌肉疾病注册表突出了球部,骨骼和近端肢体表现

BRAIN
IF11.7
2024-06-251
PRE
D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells
2024-01-187
OAAI
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
2023-10-264
OAAI
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (vol 24, pg 282, 2018)
2018-04-0113
OAAI
D-2-hydroxyglutarate interferes with HIF-1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization

D-2-hydroxyglutarate干扰HIF-1稳定性,使T细胞代谢偏向氧化磷酸化并损害Th17极化

2018-03-26100
OAAI
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

索拉非尼通过在FLT3-ITD-mutant白血病细胞中产生IL-15促进小鼠和人类的移植物抗白血病活性

2018-02-12236
OAAI